Rein Therapeutics (RNTX) Minority Interest (2016 - 2017)
Rein Therapeutics (RNTX) posted quarterly Minority Interest of $130.4 million for Q2 2017, up 0.51% quarter-over-quarter from $129.7 million in Q4 2016.
Rein Therapeutics (RNTX) Minority Interest (2016 - 2017) Analysis & Trends
Rein Therapeutics (RNTX) has reported Minority Interest for 2 consecutive years, with $130.4 million the latest figure, recorded in Q2 2017.
- In Q2 2017, Minority Interest changed N/A year-over-year to $130.4 million; the TTM figure through Jun 2017 stood at $130.4 million (changed N/A YoY), while the FY2016 annual figure was $129.7 million, up 32.83% from the prior year.
- Minority Interest advanced to $130.4 million in Q2 2017 per RNTX's latest filing, from $129.7 million in the prior quarter.
- Across five years, Minority Interest topped out at $130.4 million in Q2 2017 and bottomed at $129.7 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 130.41 Mn |
| Dec 31, 2016 | 129.75 Mn |